828 Winter Street
Suite 300
Waltham, MA 02451
United States
857 524 2466
https://xiliotx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 73
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Rene Russo BCPS, Pharm.D. | President, CEO & Director | 875.13k | N/A | 1975 |
Mr. Christopher Frankenfield | Chief Operating Officer | 704.85k | N/A | 1982 |
Dr. Katarina Luptakova M.D. | Chief Medical Officer | 591.92k | N/A | 1976 |
Mr. Kevin M. Brennan | Senior VP of Finance & Accounting | N/A | N/A | 1970 |
Dr. Uli Bialucha Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Stacey J. Davis | Chief Business Officer | N/A | N/A | N/A |
Dr. Scott Coleman Ph.D. | Chief Development Officer | N/A | N/A | N/A |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.